SCHEMBL5877571

SCHEMBL5877571

COc1ccc(OC)c(C=CC=O)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 0.69
CYP1B1 Q16678 6/20 0.69
CYP1A2 P05177 5/20 0.69
NFE2L2 Q16236 3/20 0.69
JUN P05412 1/20 0.63
NFKB1 P19838 1/20 0.63
ABCG2 Q9UNQ0 1/20 0.58
CYP19A1 P11511 1/20 0.55
PDE4A P27815 1/20 0.55
PDE4B Q07343 1/20 0.55
PDE4C Q08493 1/20 0.55
PDE4D Q08499 1/20 0.55
ALDH1A1 P00352 2/20 0.53
TLR9 Q9NR96 1/20 0.52
MAPT P10636 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
ATM Q13315 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2121298 1.00 CYP1A1 (0.69) CYP1A1CYP1B1CYP1A2NFE2L2JUN
SCHEMBL11874692 0.89 CYP1A1 (0.79) CYP1A1CYP1B1CYP1A2NFE2L2JUN
SCHEMBL11874684 0.89 CYP1A1 (0.79) CYP1A1CYP1B1CYP1A2NFE2L2JUN
SCHEMBL4624144 0.87 CYP1A2 (0.75) CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1
SCHEMBL714242 0.87 CYP1A2 (0.75) CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1
SCHEMBL29575647 0.87 CYP1A2 (0.75) CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1
SCHEMBL15932971 0.82 CYP1A1 (0.69) CYP1A1CYP1B1CYP1A2NFE2L2JUN
SCHEMBL21030089 0.81 CYP1A1 (1.00) CYP1A1CYP1B1CYP1A2NFE2L2CYP19A1
SCHEMBL1759669 0.81 CYP1A1 (0.58) CYP1A1CYP1B1CYP1A2NFE2L2JUN
SCHEMBL172939 0.81 ALDH1A1 (0.71) CYP1A1CYP1B1CYP1A2NFE2L2JUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376441-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT UNIV YONSEI IACF (KR) 2025-12-11 US disclosed
US-20200190024-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2020-06-18 US disclosed
US-7060706-B1 Quinazolinones 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-06-13 US disclosed
US-20050203170-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof AVENTIS PHARMA S.A. 2005-09-15 US disclosed
US-6890930-B1 Quinazolinones 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-05-10 US disclosed
US-20040147584-A2 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-07-29 US disclosed
US-20030153611-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof AVENTIS PHARMA S.A. 2003-08-14 US disclosed
EP-1216235-A1 QUINAZOLINONES MERCK PATENT GmbH (DE) 2002-06-26 EP disclosed
EP-1216233-A1 QUINAZOLINONES MERCK PATENT GmbH (DE) 2002-06-26 EP disclosed
WO-2001023365-A1 QUINAZOLINONES MERCK PATENT GMBH (DE) 2001-04-05 WO disclosed
WO-2001023364-A1 QUINAZOLINONES MERCK PATENT GMBH (DE) 2001-04-05 WO disclosed
US-3947337-A α,ω-Diarylpolyene photosensitizers for sulfonylazide polymers THE UPJOHN COMPANY (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147584-A2 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF MCL1, ENPP1, MYC CYP1A1 24/4885CYP1B1 6/4885CYP1A2 367/4885
US-20200190024-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT PRKAA1, PRKAA2, PRKAG1 CYP1A1 4083/4885CYP1B1 4227/4885CYP1A2 4142/4885
US-20250376441-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT PRKAA1, PRKAA2, PRKAG1 CYP1A1 4083/4885CYP1B1 4227/4885CYP1A2 4142/4885
US-20050203170-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof MCL1, ENPP1, MYC CYP1A1 24/4885CYP1B1 6/4885CYP1A2 367/4885
US-20030153611-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof MCL1, ENPP1, MYC CYP1A1 24/4885CYP1B1 6/4885CYP1A2 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.